- Five times better resolution of empty/full capsids
- Large scale removal of empty, partial and heavy AAV capsids
- Batch-to-batch and scale-to-scale reproducibility within +/- 3%

- Emerging Diagnostic Technologies
- Precision Medicine and Special Population
- The Lab's Role in Advancing Equity
- Regulatory Compliance for Clinical Diagnostics

- How to increase pipetting accuracy and repeatability with electronic pipettes
- How connected electronic pipettes reduce the time needed to collect results
- How researchers can semi-automate workflows with connected electronic pipettes

- Production of rAAV at industrial scale typically involves a series of complex midstream steps, such as clarification by depth filtration and concentration/buffer exchange by tangential flow filtration.
- We developed a filter-less flow capture method for purification of rAAV serotype 5, using a high-gradient magnetic separator and magnetic Mag Sepharose beads coupled to an AVB affinity ligand.
- In under 2 h, we captured and eluted rAAV5 directly from ∼ 5 L of cell lysate with satisfying recovery, yield, and purity. The developed process simplifies purification of rAAV.

- Expansion of CAR-T cells in automated stirred-tank bioreactors.
- Scalability from 15 mL culture
- to 1 L.
- Identification of the optimal perfusion parameters to maximize cellular growth, quality, and functionality of CAR-T cells.

- Adeno-associated viruses (AAVs) are widely used vectors for gene therapies mainly due to their favorable safety profile and high transduction efficiency to various target tissues. With increasing demand for faster process development of advanced therapies using AAVs, rapid at-line analytical chromatographic solutions are becoming indispensable.
- PATfix analytical system with multiple detectors seamlessly delivers coherent process information, considerably speeding up process development and enabling a fast-paced delivery of the product to the market.
- Analytical methods, embedded in the PATfix system that enables at-line monitoring of common product and process related impurities, provide a critical platform for the rapid development and characterization of AAV-based gene therapy vectors.